Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its majority-owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval from the National Medical Products Administration for a new indication of its drug, Lumvatinib tablets (brand name: Fumaining, project code: FCN-159).

The newly approved indication covers adult patients with neurofibromatosis type 1 (NF1) who present with symptomatic, inoperable plexiform neurofibromas (PN). This marks a significant expansion of the drug's approved uses.

Lumvatinib is an innovative small-molecule chemical drug developed in-house by the group, functioning as a selective inhibitor of MEK1/2. The approval of this additional indication is expected to offer a new therapeutic option for patients suffering from related rare tumors within China, while also strengthening the drug's competitive position in the market.